Moderna, Merck's Personalized Cancer Vaccine Shows Promise.
Moderna and Merck said Wednesday their personalized cancer vaccine met key goals in its first large, late-stage trial. The treatment reduced both melanoma recurrence and distant spread compared with Keytruda alone.
- 1,137 high-risk patients with surgically removed stage IIB-IV melanoma enrolled in the trial.
- 49% reduction in recurrence risk was reported in earlier Phase 2 data after five years.
- Moderna shares rose as much as 106% in premarket trading; Merck climbed roughly 7%.
- Analysts estimate the approved product could generate more than $6 billion in annual melanoma sales.
Why it matters: The trial is the first Phase 3 study to validate personalized cancer vaccines, a concept researchers have pursued for over a century. Success opens a potential path to treating lung, bladder, and kidney cancers with the same approach.
- Each vaccine is built from genetic sequencing of a patient's own tumor, targeting mutations unique to that individual rather than applying a single formula.
- Melanoma causes the large majority of skin-cancer deaths despite representing only about 1% of skin cancer cases.
How 18 sources split on this story
Where they split: The companies have not released detailed trial data or published results in a peer-reviewed journal, leaving independent verification pending.
Center coverage, 8 sources: The center focuses on the clinical milestone and near-term regulatory path, treating the result as significant but conditional on full data presentation.
CNBC4hPersonalized cancer vaccine from Moderna, Merck shows promise in first late-stage melanoma trial
Reuters58mErfolgreiche Studie zu Hautkrebs-Impfstoff beflügelt Moderna
Financial Times2hModerna share price doubles on melanoma vaccine trial success
Forbes1hModerna Shares Skyrocket 90% Toward Best Day Ever—Here’s Why
MarketWatch3hModerna’s stock doubles on promising cancer-vaccine results
Newsweek2hModerna cancer trial success is a shot in the arm for Trump
Sky News2hModerna's share price nearly doubles on hopes of cancer treatment breakthrough
USA Today52mMerck, Moderna's melanoma skin cancer vaccine succeeds in late-stage trialLeft coverage, 6 sources: The left emphasizes patient hope and the mRNA platform's broader potential, while noting that detailed data remain unreleased and that political headwinds around mRNA research add uncertainty.
CNN3hModerna shares surge as melanoma vaccine with Merck succeeds in large trial
The Independent1hSkin cancer vaccine shows promise in preventing recurrence of melanoma in large trial
NBC News2hMerck and Moderna say cancer vaccine shows promise in preventing recurrence of melanoma
The Washington Post3hCancer treatment could face landmark moment with promising vaccine...
Time1hPromising Results for mRNA Cancer Vaccine from Moderna and MerckRight coverage, 4 sources: The right leads with the dramatic stock surge and frames the result as a potential breakthrough moment that validates Moderna's post-pandemic pivot.
ZeroHedge3hHoly Grail In Cancer Treatment? Moderna Erupts After Melanoma Vaccine Late-Stage Trial Success
Citizen Free Press5hModerna and Merck cancer vaccine shows promise — Moderna stock soars 90 percent.
The Epoch Times15hmRNA Cancer Vaccine Succeeds in Late-Stage Trial, Companies Say
Washington Examiner23mModerna stock prices double on claimed mRNA cancer vaccine breakthroughWhat’s next: Full results will be presented at an international medical meeting, date not yet set.
- Moderna's president said an FDA filing is expected in months, not years.
- Whether the treatment extends overall survival remains unanswered; the trial continues.
- Will full data, once published, confirm the interim results reported in the press release?
- Does the combination extend overall survival, or only delay recurrence?
- Can the personalized manufacturing process scale quickly enough for broad commercial use?